Neurocrine Biosciences (NBIX) Return on Equity [ROE] (2011 - 2026)
Neurocrine Biosciences (NBIX) reported Return on Equity [ROE] of 19.87% for Q2 2026, up 6.55 percentage points from 13.32% a year earlier but down 0.21 percentage points from the prior quarter.
Powered by 
Analysis
Neurocrine Biosciences (NBIX) Return on Equity [ROE] (2011 - 2026) Analysis & Trends
For FY2025, Neurocrine Biosciences posted Return on Equity [ROE] of 16.38%, up 2.23 percentage points from FY2024.
- Return on Equity [ROE] has increased for four consecutive years, though with a five-year change of -29.82 percentage points (FY2020 to FY2025).
- By year, Return on Equity [ROE] came in at 14.16% in FY2024 (+1.48 pp), 12.68% in FY2023 (+2.65 pp), 10.03% in FY2022 (+2.86 pp) and 7.17% in FY2021 (-39.04 pp).
- Five-year quarterly Return on Equity [ROE] spans a low of 0.87% in Q2 2022 and a high of 33.89% in Q3 2021.
- Year over year, Return on Equity [ROE] has now increased in each of the last four quarters, with an average year-over-year change of +2.34 percentage points over the last eight quarters.
- The high point for year-over-year Return on Equity [ROE] in five years was Q3 2021 (a gain of 22.47 percentage points); the low point was Q4 2021 (a drop of 35.61 percentage points).
- Per Business Quant data, the three quarters before Q2 2026 came in at 20.08% (Q1 2026), 15.30% (Q4 2025) and 15.02% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROE (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,175.39 Bn | 1,143.98 Bn | 19.71 Bn | 82.09% |
| 2 | Johnson & Johnson | 639.10 Bn | 557.63 Bn | 17.26 Bn | 25.32% |
| 3 | AbbVie | 502.70 Bn | 475.81 Bn | 12.70 Bn | - |
| 4 | Merck | 376.68 Bn | 331.05 Bn | 12.21 Bn | 7.21% |
| 5 | Novartis Ag | 304.33 Bn | 268.32 Bn | 11.24 Bn | 31.52% |
| 6 | Astrazeneca | 267.75 Bn | 241.43 Bn | 12.86 Bn | 21.39% |
| 7 | Amgen | 242.34 Bn | 197.73 Bn | 7.24 Bn | 83.75% |
| 8 | Gilead Sciences | 193.67 Bn | 167.87 Bn | 6.22 Bn | -18.38% |
| 9 | Pfizer | 172.62 Bn | 119.27 Bn | 10.94 Bn | 4.97% |
| 10 | Neurocrine Biosciences | 14.27 Bn | 9.96 Bn | 935.80 Mn | 19.87% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 19.87% |
| Mar 31, 2026 | 20.08% |
| Dec 31, 2025 | 15.30% |
| Sep 30, 2025 | 15.02% |
| Jun 30, 2025 | 13.32% |
| Mar 31, 2025 | 11.93% |
| Dec 31, 2024 | 12.86% |
| Sep 30, 2024 | 14.76% |
| Jun 30, 2024 | 13.86% |
| Mar 31, 2024 | 16.01% |
| Dec 31, 2023 | 11.79% |
| Sep 30, 2023 | 9.91% |
| Jun 30, 2023 | 9.97% |
| Mar 31, 2023 | 3.77% |
| Dec 31, 2022 | 9.50% |
| Sep 30, 2022 | 3.92% |
| Jun 30, 2022 | 0.87% |
| Mar 31, 2022 | 5.16% |
| Dec 31, 2021 | 6.59% |
| Sep 30, 2021 | 33.89% |
API Access
Neurocrine Biosciences Return on Equity [ROE] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=NBIX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-equity-[roe]", "ticker": "NBIX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=NBIX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();